Healthcare firm Glenmark Pharma is set to declare its results for the third quarter of financial year 2012-13 on Tuesday. Analysts on an average expect profit after tax to grow 4 times year-on-year to Rs 181 crore in the quarter due to EBITDA expansion and one off income.
Analysts expect profit after tax in the range of Rs 161 crore to Rs 205 crore for the third quarter.
In a year ago quarter (Q3FY12), margins contracted due to growth from lower margin regions and PAT contracted due EBITDA pressure plus forex loss of Rs 102 crore.
Revenues are expected to go up by 22 percent to Rs 1,258 crore from Rs 1,031 crore during the same period.
Earnings before interest, tax, depreciation and amortisation (EBITDA) are likely to jump 152 percent YoY to Rs 260 crore in October-December quarter.
Analysts expect operating profit margin to be doubled to 20.7 percent in December quarter 2012 as against 10 percent in a year ago period.
Glenmark will receive a USD 9 million (Rs 49 crore) upfront income on account of the licensing deal signed with Forest Labs in the quarter.
Besides milestone payment from Forest, the topline momentum will sustain with India and US as key drivers, say analysts.
According to analysts, domestic market will outperform the market growth with atleast 20 percent growth as against industry rate of 14 percent.
Even spate of new launches i.e. Malarone / Oral Contraceptives will help aid the US business. Segment wise performance in Q2FY13
Generics business grew 45 percent YoY to Rs 579 crore and speciality (ex-licensing) jumped 30.4 percent YoY to Rs 669 crore in October-December quarter. Geographic break up (Q2FY13) – strong numbers
US generics business rose by 44 percent YoY to Rs 431 crore
EU formulations went up by 109 percent YoY to Rs 38 crore
Indian business grew by 35.5 percent YoY to Rs 344 crore
Africa / Asia / CIS were up 31 percent YoY to Rs 194 crore
Latin America / Caribbean rose by 27 percent YoY to Rs 94 crore
API business grew by 35 percent YoY to Rs 103 crore.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
